Chantix and Zyban Get Boxed Warnings

August 2009
Pharmaceutical Representative;Aug2009, Vol. 39 Issue 8, p11
The article reports on that the U.S. Food and Drug Administration (FDA) had mandated that smoking cessation drugs Chantix (varenicline) and Zyban (buproprion) must bear black box warnings for serious mental health symptoms. The announcement came following complaints from consumers taking Chantix who reported that they had become increasingly depressed. Buproprion is also marketed as the antidepressent Wellbutrin.


Related Articles

  • Varenicline Gets Stronger Warnings About Psychiatric Problems, Vehicle Crashes. Kuehn, Bridget M. // JAMA: Journal of the American Medical Association;8/26/2009, Vol. 302 Issue 8, p834 

    The article reports on the requirement imposed by the U.S. Food and Drug Administration (FDA) on manufacturers of smoking cessation drug varenicline to place a boxed warning on the drug's label to alert physicians and patients to the risks associated with it. It notes that the revised labeling...

  • Black boxes for Chantix and Zyban.  // Reactions Weekly;7/11/2009, Issue 1260, p2 

    The article reports on the move by the U.S. Food and Drug Administration (FDA) to require manufacturers of the smoking cessation drugs varenicline and bupropion to add data on the risk of serious neuropsychiatric disorders to the Boxed Warnings and Warning sections of the prescribing information...

  • FDA's postmarketing review of varenicline and bupropion.  // Reactions Weekly;1/24/2009, Issue 1236, p3 

    The article reports on the postmarketing review of Adverse Event Reporting System reports by the U.S. Food and Drug Administration (FDA) which identified cases of suicidal ideation and behaviours after taking varenicline and bupropion for smoking cessation. 41 percent of varenicline recipients...

  • NEWSLINE.  // Monthly Prescribing Reference;Sep2010, Vol. 26 Issue 9, pA9 

    The article offers news briefs related to drugs. Labopharm and Angelini have made the drug Oleptro available for major depressive disorder (MDD). The U.S. Food and Drug Administration (FDA) is examining clinical trial data suggesting that Stalevo from Novartis increased the risk for...

  • Caution about antidepressant use.  // Patient Care;Jun2004, Vol. 38 Issue 6, p10 

    Report on the advice of the U.S. Food and Drug Administration (FDA) regarding the use of antidepressant. Possible effects of antidepressant use; Suggestions for physicians during the early period of the patient's treatment and at the time that dosages are increased or decreased; Recommendation...

  • FDA issues advisory about antidepressants….  // Drug Topics;4/5/2004, Vol. 148 Issue 7, p8 

    Reports that the U.S. Food & Drug Administration has requested that manufacturers of antidepressants include in their labeling a warning statement recommending close observation of patients for worsening depression and suicidality when treated with the drugs. List of drugs affected by the warning.

  • US physicians heed warnings over paediatric antidepressant use.  // PharmacoEconomics & Outcomes News;10/9/2004, Issue 463, p7 

    Reports on the outcome of the warning issued by the U.S. Food & Drug Administration (FDA) concerning paediatric antidepressant use. Decrease in the number of paediatric patients receiving the drug; Risks associated with the use of the drug; Antidepressant drug labeling changes required by the FDA.

  • Special Report: FDA's varenicline update.  // Cortlandt Forum;Jan2008, Vol. 21 Issue 1, p8 

    The article provides information on the report released by the U.S. Food and Drug Administration (FDA) regarding the side effects of varenicline, trade name Chantix, a drug to help adults quit smoking. The FDA has reported cases of suicidal thoughts, aggressive and eratic behavior in some...

  • Smoking Cessation and Psychiatric Effects.  // Clinical Cardiology Alert;Sep2009 Pharmacology Watch, p2 

    The article reports on an advice given by the U.S. Food and Drug Administration (FDA) to patients who are using the smoking cessation drugs varenicline and bupropion. The FDA urges patients to withdraw from using the drug if they develop behavioral changes, agitation, depression or suicidal...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics